# Pattern Bioscience

> Pattern Bioscience is an Austin biotechnology company developing a single-cell microbiology system for rapid pathogen identification and phenotypic antibiotic susceptibility testing. Its initial pneumonia panel analyzes respiratory specimens directly, using droplet microfluidics, metabolic signals and machine learning to guide targeted antibiotic treatment; urinary tract and bloodstream programs extend the platform.

- **Founded:** 2016
- **Headquarters:** Austin, United States
- **Founders:** Nick Arab (Founder and Chief Technology Officer; formerly CEO), Ross Johnson (Co-founder and Chief Engineer), Bryan Gammon (Co-founder, identified in CARB-X’s 2022 company history; current operating role unverified)
- **Products:** Pattern System / Digital Culture technology, Pneumonia ID/AST Panel, Bacteremia ID/AST Panel, Urine ID/AST Panel
- **Notable:** FDA Breakthrough Device Designation for pneumonia panel announced December 2021., Winner of ADLM’s 2023 Disruptive Technology Award., BARDA base contract award of $22.5 million announced November 2024.

## Products & services

- **Pattern System / Digital Culture technology** — Investigational single-cell microbiology platform combining droplet isolation, fluorescence-based metabolic analysis and machine learning for pathogen identification and phenotypic AST. Not a consumer diagnostic service.
- **Pneumonia ID/AST Panel** — First planned commercial assay, for critically ill patients with suspected pneumonia; direct-from-respiratory-specimen ID and phenotypic susceptibility testing. Breakthrough designation announced in 2021; pivotal validation underway in 2026.
- **Bacteremia ID/AST Panel** — Bloodstream-infection program supported by the 2024 BARDA contract; in development.
- **Urine ID/AST Panel** — Direct-from-specimen urinary tract infection program; FDA Breakthrough Device Designation announced September 2026, not cleared or available for sale at that announcement.

## Achievements

- FDA Breakthrough Device Designation for pneumonia panel announced December 2021.
- Winner of ADLM’s 2023 Disruptive Technology Award.
- BARDA base contract award of $22.5 million announced November 2024.
- More than 1,000 samples enrolled in pivotal pneumonia study by March 19, 2026.
- Second Breakthrough Device Designation, for Urine ID/AST Panel, announced September 21, 2026.

## Latest updates

- **2026-03** — Pivotal pneumonia clinical trial surpassed 1,000 enrolled samples; approximately 2,000 planned across 11 external sites.
- **2026-07** — David Barreca appointed VP of Sales to build the U.S. commercial organization as Pattern approached submission and launch.
- **2026-09** — Urine ID/AST Panel received FDA Breakthrough Device Designation; company explicitly states designation is not clearance or approval and panel is not for sale.

## Links

- Website: https://pattern.bio/
- LinkedIn: https://www.linkedin.com/company/patternbio
- Twitter/X: https://twitter.com/Patternbio
- Instagram: https://www.instagram.com/pattern.bio/
- Facebook: https://facebook.com/patternbio

---

Profile page: https://yespress.io/pattern-bioscience
Published by YesPress — https://yespress.io
Last updated: 2026-10-04